JUND — patent landscape

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL2117317	1.00	1/20
SCHEMBL13726132	0.71	1/20
SCHEMBL2116061	0.70	1/20
SCHEMBL13724800	0.69	1/20
SCHEMBL13725202	0.68	1/20
SCHEMBL2804418	0.68	1/20
SCHEMBL14680373	0.68	1/20
SCHEMBL14758490	0.68	1/20
SCHEMBL13725690	0.67	1/20
SCHEMBL10077001	0.66	1/20
SCHEMBL13726071	0.65	1/20
SCHEMBL13726075	0.65	1/20
SCHEMBL2117400	0.65	1/20
SCHEMBL13856742	0.65	1/20
SCHEMBL23949485	0.64	1/20
SCHEMBL13725582	0.63	1/20
SCHEMBL13726141	0.63	1/20
SCHEMBL13856221	0.63	1/20
SCHEMBL13725212	0.62	1/20
SCHEMBL13056428	0.62	1/20

Clinical trials — most relevant to JUND by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Mechanisms of Lipodystrophy in HIV-Infected Pateints	PHASE4	COMPLETED
Effects of Repetitive Transcranial Magnetic Stimulation in the Treatment of Phantom Limb Pain in Landmine Victims: ANTARES	PHASE3	COMPLETED
Effects of Pioglitazone on High-density Lipoprotein (HDL) Function in Persons With Diabetes	PHASE3	COMPLETED
Prolonged Release Pirfenidone Versus Placebo in Compensated Cirrhosis.	PHASE2	COMPLETED
Phase II Trial of the Gamma-Secretase Inhibitor PF-03084014 in Adults With Desmoid Tumors/Aggressive Fibromatosis	PHASE2	COMPLETED
Study With Trabectedin in BRCA1 and BRCA2 Mutation Carrier and BRCAness Phenotype Ovarian Cancer	PHASE2	UNKNOWN
PhII 5-Azacytidine Plus Valproic Acid and Eventually Atra in Intermediate II and High Risk MDS	PHASE2	COMPLETED
PS-341 and Radiation to Treat Advanced Cancer of the Head and Neck	PHASE1	COMPLETED
Radiation Therapy and Bortezomib and Cetuximab With or Without Cisplatin to Treat Head and Neck Cancer	PHASE1	COMPLETED
Effect of Exercise on Genes That Control Muscle Function	nan	COMPLETED
Effect of Different Therapeutic Strategies on Regulatory T Cells in Kidney Transplantation	nan	COMPLETED
Non-alcoholic Fatty Liver Disease in Low Birth Weight Individuals	nan	RECRUITING
Pigeon Peas (Cajanus Cajan) : a Natural Anti-inflammatory Facilitating Weight Loss in Obese Patients Returning to Sport?	nan	UNKNOWN
Study for the Multidimensional Analyses of Resistance and Toxicity to Immune- and Targeted-therapies.	nan	UNKNOWN
Evaluation of Human Melanocytes After the Use of PRP Versus Fractional CO2 Laser in Vitiligo	nan	UNKNOWN
Timecourse of Immobilization Experiment	nan	COMPLETED
Card14gene (rs34367357 ) Polymorphism in Egyptian Psoriatic and Psoriatic Arthritis Patient	nan	RECRUITING
EKLF Gene Expression in β-thalassemia	nan	NOT_YET_RECRUITING
Abnormalities in the Effects of Insulin and Exercise on Glucose- and Lipid Metabolism in Obesity and Type 2 Diabetes	nan	COMPLETED
Role of Type 2 Diabetes in Potentiating the Inflammatory Response Post Extracorporeal Circulation After Cardiac Surgery	nan	WITHDRAWN
Evaluation of the Predictive Effect of Inflammatory Markers in MI Patients	nan	UNKNOWN
Comparison Of Efficacy Of Tazarotene 0.045% Vs Halobetasol Propionate 0.01% Lotion For Treatment of Scalp Psoriasis	nan	COMPLETED
Evaluation of the Effect of Alpha Lipoic Acid on Radiation Induced Dermatitis in Breast Cancer Patients	nan	RECRUITING
Autophagy in Systemic Lupus Erythematosus	nan	UNKNOWN
Pituitary Derived-Intermedin is an Estrogen-Modulated Factor for Reducing Blood Pressure	nan	UNKNOWN
Immune Interactions in Severe Asthma	nan	COMPLETED
Detection of Krupple Like Factor -1(KLF1/ EKLF) DNA Mutations in Beta Thalassemia Patients	nan	NOT_YET_RECRUITING
Germline Alterations of Tumor Susceptibility Genes in New York Cancer Patients	nan	ACTIVE_NOT_RECRUITING
Gene Expression, Metabolomic, Microbiome, and Calcium Metabolism in Response to Varied Vitamin D Dosages	nan	COMPLETED
Nutraceutical Composition Containing Natural Products Derivatives on the Modulation of the Endocrine Neuroimmune Axis	nan	COMPLETED

Related proteins — ESM-2 sequence neighbours (a JUND binder may also engage these)

Protein	Name	Similarity
P52909	—	0.999	P52909 →
A7YY54	—	0.998	A7YY54 →
P15066	—	0.996	P15066 →
P27921	—	0.992	P27921 →
P17275	—	0.986	P17275 →
P56432	—	0.983	P56432 →
O77627	—	0.982	O77627 →
JUN	Transcription factor Jun	0.982	landscape →
P17325	—	0.981	P17325 →
Q0VBZ5	—	0.980	Q0VBZ5 →
P09450	—	0.977	P09450 →
P24898	—	0.977	P24898 →
P05627	—	0.976	P05627 →
O35779	—	0.974	O35779 →
Q8VCG9	—	0.973	Q8VCG9 →
Q9C0J9	—	0.973	Q9C0J9 →
Q61976	—	0.972	Q61976 →
P26014	—	0.971	P26014 →
Q99PV5	—	0.970	Q99PV5 →
O00287	—	0.969	O00287 →
P03966	—	0.969	P03966 →
P04198	—	0.969	P04198 →
A6NKD9	—	0.968	A6NKD9 →
P23050	—	0.968	P23050 →
Q63379	—	0.968	Q63379 →
P12981	—	0.967	P12981 →
P18870	—	0.967	P18870 →
E9Q1P8	—	0.967	E9Q1P8 →
IRF2BP2	Interferon regulatory factor 2-binding protein 2	0.966	landscape →
Q68FF7	—	0.966	Q68FF7 →